Clinical trial
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or…
NCT00060112 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00060112 |
|---|---|
| Title | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma |
| Official title | A Phase I Study of Oblimersen (Genasense™, G3139) in Combination With Gemcitabine in Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma and 25 more |
| Intervention type | Biological, Drug, Other |
| Interventions | oblimersen sodium, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis |
| Enrollment | 15 |
| Start date | Mar 1, 2003 |
| Primary completion | Dec 1, 2009 |
| First posted | May 7, 2003 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: